Health
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial – The Lancet
This first-in-human trial shows that a subunit vaccine comprising mammalian cell culture-derived,MF59-adjuvanted, molecular clamp-stabilised recombinant spike protein…
We use cookies to help provide and enhance our service and tailor content and ads. To update your cookie settings, please visit the Cookie Preference Center for this site.Copyright © 2021 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.
Privacy Policy Terms and Conditions
-
General11 hours agoRSL NSW president Mick Bainbridge and three board members resign in wake of 7.30 investigation into conflicts of interest
-
General15 hours agoSelf-taught child drummer makes rock band debut with The Living End
-
Noosa News19 hours agoWave of cruises headed for Sunshine Coast this summer
-
General23 hours agoNewsCorp executive warns AI firms are asking Australia to ‘surrender our stories’